Zatolmilast/ BPN14770 ( DrugBank: Zatolmilast )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 206 | 脆弱Ｘ症候群 | 1 |
206. 脆弱Ｘ症候群
臨床試験数 : 108 / 薬物数 : 91 - (DrugBank : 36) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 77
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05367960 (ClinicalTrials.gov) | November 1, 2022 | 29/4/2022 | An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome | An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome | Fragile X Syndrome | Drug: Zatolmilast/ BPN14770 | Tetra Discovery Partners | NULL | Enrolling by invitation | 12 Years | 45 Years | Male | 300 | Phase 3 | United States |